PLK1-IN-13

PLK1-IN-13 is a selective and orally active PLK1 inhibitor (IC50: 0.27 nM) . PLK1-IN-13 also inhibits PLK2 (IC50: 12.72 nM) and PLK3 (IC50: 4.12 nM) . PLK1-IN-13 arrests cell at G2 phase, induces apoptosis and down-regulates the transcription of the proliferation-related oncogene c-MYC. PLK1-IN-13 inhibits tumor growth, and can be used for research of acute myeloid leukemia (AML) [1].

Product Specifications

CAS Number

[3038489-48-1]

UNSPSC

12352005

Target

Apoptosis; c-Myc; Polo-like Kinase (PLK)

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Field of Research

Cancer

Smiles

O=C1N(C)C2=CN=C(NC3=CC=C(C4=NN=C(CN5CCN(C)CC5)S4)C=C3OC)N=C2N(C6CCCC6)[C@@H]1CC

Molecular Formula

C29H39N9O2S

Molecular Weight

577.74

References & Citations

[1]Hou Y, et al. Discovery of novel dihydropteridone derivatives as orally bioavailable PLK1 inhibitors with reduced hERG inhibitory activity for acute myeloid leukemia treatment. Eur J Med Chem. 2025 May 5;289:117480.